Trial Profile
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four-Period Crossover Study to Assess the Effect of Single Doses of Corifollitropin alfa (150 mug and 240 mug) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin as a Positive Control, in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2017
Price :
$35
*
At a glance
- Drugs Corifollitropin alfa (Primary)
- Indications Female infertility
- Focus Adverse reactions
- 04 Dec 2017 New trial record